Alk-Abello AS

4AJ0

Company Profile

  • Business description

    Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

  • Contact

    Boge Alle 6-8
    HorsholmDK-2970
    DNK

    T: +45 45747576

    E: [email protected]

    https://www.alk.net

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    2,782

Stocks News & Analysis

stocks

Ask the analyst: Can this genius product create the next ASX software king?

Siteminder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
stocks

Impact of ANZ’s huge fine

Working to prevent repeated failures could also improve competitiveness.
stocks

Acquisition a sign of weakness for overvalued ASX share

Acquisition unlikely to improve prospects in the US and detracts from other opportunities.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,151.201.30-0.01%
CAC 407,818.2278.71-1.00%
DAX 4023,329.24419.62-1.77%
Dow JONES (US)45,757.90125.55-0.27%
FTSE 1009,195.6681.37-0.88%
HKSE26,438.518.05-0.03%
NASDAQ22,333.9614.79-0.07%
Nikkei 22544,902.27134.150.30%
NZX 50 Index13,234.8926.580.20%
S&P 5006,606.768.52-0.13%
S&P/ASX 2008,877.703.00-0.03%
SSE Composite Index3,861.861.360.04%

Market Movers